Profusa strategy update: $100M ELOC secured, EU launch Q1 2026, FDA submission mid-2026

Profusa, Inc.

Became public on Nasdaq July 14, 2025; strategy focused on five pillars including revenue growth and AI infrastructure.
First distributor partner in Spain for Lumee tissue oxygen platform; EU commercial launch targeted Q1 2026.
U.S. FDA submission planned mid-2026 with U.S. commercialization anticipated mid-2027 for oxygen monitoring.
Continuous glucose monitoring: human validation data expected in peer-reviewed journal; pivotal studies later 2026.
Secured $100M ELOC facility and implementing digital investment treasury plan to support growth.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.